{"id":282792,"date":"2026-10-01T10:21:41","date_gmt":"2026-10-01T04:51:41","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=282792"},"modified":"2026-10-01T10:21:41","modified_gmt":"2026-10-01T04:51:41","slug":"symbiotec-pharmalab-share-price-us-deal","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-share-price-us-deal\/","title":{"rendered":"Symbiotec&#8217;s US Arm Signs an Exclusive Deal for Two Injectables, and the Stock Touches a Fresh 52-Week High"},"content":{"rendered":"<p style=\"border-left:4px solid #1F4E79;background:#EBF3FB;padding:10px 16px;font-style:italic;\"><em>Symbiotec Pharmalab Rs 1,198, up 1.8% (1 Oct, 10:12 AM), fresh 52-week high Rs 1,222.50. Subsidiary Knovea signs exclusive US deal for 2 dual-chamber vial injectables. P\/E 68.77.<\/em><\/p>\n<div style=\"background:#F0F9FF;border-left:4px solid #2E7D32;border-radius:6px;padding:14px 18px;margin:18px 0;\">\n<p style=\"margin:0;color:#1F4E79;font-size:14px;\"><strong>Quick Answer<\/strong><\/p>\n<p style=\"margin:8px 0 0;\">The Symbiotec Pharmalab share price was Rs 1,198 at 10:12 AM on 1 October 2026, up 1.8 percent, after touching a fresh 52-week high of Rs 1,222.50, following news that subsidiary Knovea Pharmaceutical has entered a definitive agreement with a leading global pharmaceutical company. The agreement grants the partner exclusive rights to commercialise and distribute two dual-chamber vial-based injectable products in the United States. The disclosure did not name the partner company or disclose financial terms such as upfront payments, milestones or royalty rates. Symbiotec trades at a P\/E of 68.77 against a pharmaceutical industry average of 38.34, a significant premium that reflects the market&#8217;s expectations for its specialised injectables pipeline.<\/p>\n<\/div>\n<p>Symbiotec Pharmalab Limited said its wholly owned subsidiary Knovea Pharmaceutical has entered into a definitive agreement with a leading global pharmaceutical company, granting the partner exclusive rights to commercialise and distribute two dual-chamber vial-based injectable products in the United States. The announcement did not name the partner or disclose the financial terms of the agreement.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/user\/log-in?utm_source=blogs&#038;utm_medium=symbiotec-pharmalab-share-price-us-deal\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<p>The Symbiotec Pharmalab share price rose to a fresh 52-week high of Rs 1,222.50 on the news, extending a strong run for the stock. This article covers what the deal involves, the company&#8217;s current valuation, and the risks for investors.<\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-share-price-us-deal\/#What_the_Knovea_Pharmaceutical_US_Deal_Involves\" title=\"What the Knovea Pharmaceutical US Deal Involves\">What the Knovea Pharmaceutical US Deal Involves<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-share-price-us-deal\/#Symbiotec_Pharmalab_Share_Price_Today_Numbers_and_Technical_Levels\" title=\"Symbiotec Pharmalab Share Price Today: Numbers and Technical Levels\">Symbiotec Pharmalab Share Price Today: Numbers and Technical Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-share-price-us-deal\/#Valuation_Behind_the_Symbiotec_Pharmalab_Share_Price\" title=\"Valuation Behind the Symbiotec Pharmalab Share Price\">Valuation Behind the Symbiotec Pharmalab Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-share-price-us-deal\/#Risks_for_the_Symbiotec_Pharmalab_Share_Price\" title=\"Risks for the Symbiotec Pharmalab Share Price\">Risks for the Symbiotec Pharmalab Share Price<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-share-price-us-deal\/#Conclusion\" title=\"Conclusion\">Conclusion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-share-price-us-deal\/#Frequently_Asked_Questions\" title=\"Frequently Asked Questions\">Frequently Asked Questions<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-share-price-us-deal\/#What_is_the_Symbiotec_Pharmalab_share_price_today\" title=\"What is the Symbiotec Pharmalab share price today?\">What is the Symbiotec Pharmalab share price today?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-share-price-us-deal\/#What_deal_has_Symbiotecs_subsidiary_signed\" title=\"What deal has Symbiotec&#8217;s subsidiary signed?\">What deal has Symbiotec&#8217;s subsidiary signed?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-share-price-us-deal\/#Who_is_the_partner_in_the_Knovea_Pharmaceutical_deal\" title=\"Who is the partner in the Knovea Pharmaceutical deal?\">Who is the partner in the Knovea Pharmaceutical deal?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-share-price-us-deal\/#Were_financial_terms_of_the_deal_disclosed\" title=\"Were financial terms of the deal disclosed?\">Were financial terms of the deal disclosed?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-share-price-us-deal\/#Is_the_Symbiotec_Pharmalab_share_price_expensive\" title=\"Is the Symbiotec Pharmalab share price expensive?\">Is the Symbiotec Pharmalab share price expensive?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-share-price-us-deal\/#What_are_the_key_technical_levels_for_the_Symbiotec_Pharmalab_share_price\" title=\"What are the key technical levels for the Symbiotec Pharmalab share price?\">What are the key technical levels for the Symbiotec Pharmalab share price?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-share-price-us-deal\/#What_is_a_dual-chamber_vial_injectable\" title=\"What is a dual-chamber vial injectable?\">What is a dual-chamber vial injectable?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/symbiotec-pharmalab-share-price-us-deal\/#Should_I_buy_Symbiotec_Pharmalab_shares_after_this_news\" title=\"Should I buy Symbiotec Pharmalab shares after this news?\">Should I buy Symbiotec Pharmalab shares after this news?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"What_the_Knovea_Pharmaceutical_US_Deal_Involves\"><\/span><strong>What the Knovea Pharmaceutical US Deal Involves<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellpadding=\"6\" style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th style=\"text-align:left;\">Item<\/th>\n<th style=\"text-align:left;\">Detail<\/th>\n<\/tr>\n<tr>\n<td>Signing entity<\/td>\n<td>Knovea Pharmaceutical (wholly owned subsidiary of Symbiotec Pharmalab)<\/td>\n<\/tr>\n<tr>\n<td>Counterparty<\/td>\n<td>A leading global pharmaceutical company (unnamed)<\/td>\n<\/tr>\n<tr>\n<td>Rights granted<\/td>\n<td>Exclusive commercialisation and distribution<\/td>\n<\/tr>\n<tr>\n<td>Products<\/td>\n<td>Two dual-chamber vial-based injectable products<\/td>\n<\/tr>\n<tr>\n<td>Territory<\/td>\n<td>United States<\/td>\n<\/tr>\n<tr>\n<td>Financial terms disclosed<\/td>\n<td>None<\/td>\n<\/tr>\n<\/table>\n<p>Dual-chamber vial technology allows two components, such as a drug and a diluent, to be kept separate until just before administration, which is a specialised and technically demanding injectable format. An exclusive US distribution deal for this kind of complex generic or specialty injectable typically signals meaningful technical capability on the manufacturing side, even without the specific commercial terms being disclosed.<\/p>\n<p style=\"font-style:italic;color:#000000;margin:14px 0;\">Also read &#8211; <a href=\"https:\/\/univest.in\/blogs\/stocks-to-watch-today-01102026\">Stocks to Watch Today: Alicon Castalloy Jumps 20%, Ircon and Rites Surge on Heavy Volume<\/a><\/p>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Symbiotec_Pharmalab_Share_Price_Today_Numbers_and_Technical_Levels\"><\/span><strong>Symbiotec Pharmalab Share Price Today: Numbers and Technical Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellpadding=\"6\" style=\"border-collapse:collapse;width:100%;\">\n<tr>\n<th style=\"text-align:left;\">Metric<\/th>\n<th style=\"text-align:left;\">Value (1 Oct, 10:12 AM)<\/th>\n<\/tr>\n<tr>\n<td>Symbiotec Pharmalab share price<\/td>\n<td>Rs 1,198.00 (up 1.8%)<\/td>\n<\/tr>\n<tr>\n<td>Previous close<\/td>\n<td>Rs 1,176.75<\/td>\n<\/tr>\n<tr>\n<td>Fresh 52-week high<\/td>\n<td>Rs 1,222.50<\/td>\n<\/tr>\n<tr>\n<td>52-week low<\/td>\n<td>Rs 934.20<\/td>\n<\/tr>\n<tr>\n<td>RSI (14-day)<\/td>\n<td>55.3<\/td>\n<\/tr>\n<tr>\n<td>SuperTrend<\/td>\n<td>Bullish, support at Rs 980.78<\/td>\n<\/tr>\n<tr>\n<td>20-day average<\/td>\n<td>Rs 1,097.93<\/td>\n<\/tr>\n<tr>\n<td>Market cap<\/td>\n<td>Rs 7,557 crore<\/td>\n<\/tr>\n<tr>\n<td>P\/E vs industry P\/E<\/td>\n<td>68.77 vs 38.34<\/td>\n<\/tr>\n<\/table>\n<p>The Symbiotec Pharmalab share price is at a fresh 52-week high, up 28.3 percent from its 52-week low of Rs 934.20 and well above its 20-day average of Rs 1,097.93. An RSI of 55.3 is neutral to mildly positive, and the SuperTrend indicator remains bullish with support at Rs 980.78.<\/p>\n<p style=\"margin-top:24px;\"><a href=\"https:\/\/univest.in\/screeners\"><strong>Compare Pharma and Injectables Stocks on the Univest Screener<\/strong><\/a><\/p>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Valuation_Behind_the_Symbiotec_Pharmalab_Share_Price\"><\/span><strong>Valuation Behind the Symbiotec Pharmalab Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Symbiotec trades at a P\/E of 68.77, nearly double the pharmaceutical industry average of 38.34. Return on equity of 9.56 percent is relatively modest relative to this valuation, suggesting the market is pricing in substantial future growth in the company&#8217;s specialised injectables business rather than current profitability.<\/p>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Risks_for_the_Symbiotec_Pharmalab_Share_Price\"><\/span><strong>Risks for the Symbiotec Pharmalab Share Price<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Valuation risk is the central concern, since a P\/E nearly double the industry average, against a modest 9.56 percent return on equity, leaves the stock exposed if the specialised injectables pipeline does not convert into revenue as quickly as the market expects. The lack of disclosed financial terms for the Knovea deal means investors cannot yet assess its direct earnings impact. US regulatory approval and manufacturing compliance risk, standard for any company exporting injectables to the US market, is a further factor to watch.<\/p>\n<p style=\"margin-top:24px;\"><em>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&#038;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to track the Symbiotec Pharmalab share price and get alerts on US deal updates.<\/em><\/p>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Conclusion\"><\/span><strong>Conclusion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The Symbiotec Pharmalab share price touched a fresh 52-week high after subsidiary Knovea Pharmaceutical signed an exclusive US deal for two dual-chamber vial injectables, though financial terms were not disclosed. A bullish technical trend supports the stock, while a P\/E nearly double the pharma industry average and the undisclosed deal economics are the risks to weigh. Investors deciding whether to buy Symbiotec Pharmalab shares should watch the Rs 1,097.93 average as support, follow stop-loss levels and consult a SEBI-registered adviser.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data independently before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"What_is_the_Symbiotec_Pharmalab_share_price_today\"><\/span><strong>What is the Symbiotec Pharmalab share price today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The Symbiotec Pharmalab share price was Rs 1,198 at 10:12 AM on 1 October 2026, up 1.8 percent, after touching a fresh 52-week high of Rs 1,222.50.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"What_deal_has_Symbiotecs_subsidiary_signed\"><\/span><strong>What deal has Symbiotec&#8217;s subsidiary signed?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Knovea Pharmaceutical, a wholly owned subsidiary of Symbiotec Pharmalab, signed a definitive agreement granting a global pharmaceutical company exclusive US rights to commercialise two dual-chamber vial-based injectable products.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Who_is_the_partner_in_the_Knovea_Pharmaceutical_deal\"><\/span><strong>Who is the partner in the Knovea Pharmaceutical deal?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The partner&#8217;s name was not disclosed in the announcement reviewed.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Were_financial_terms_of_the_deal_disclosed\"><\/span><strong>Were financial terms of the deal disclosed?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> No. The agreement&#8217;s financial terms, including any upfront payments or royalties, were not disclosed.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Is_the_Symbiotec_Pharmalab_share_price_expensive\"><\/span><strong>Is the Symbiotec Pharmalab share price expensive?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The P\/E of 68.77 is nearly double the pharmaceutical industry average of 38.34, reflecting high growth expectations.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"What_are_the_key_technical_levels_for_the_Symbiotec_Pharmalab_share_price\"><\/span><strong>What are the key technical levels for the Symbiotec Pharmalab share price?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The key levels are SuperTrend support at Rs 980.78 and the 20-day average of Rs 1,097.93. The RSI is 55.3.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"What_is_a_dual-chamber_vial_injectable\"><\/span><strong>What is a dual-chamber vial injectable?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> It is a specialised injectable format that keeps two components, such as a drug and a diluent, separate until just before administration.<\/p>\n<h3 style=\"font-weight:700;\"><span class=\"ez-toc-section\" id=\"Should_I_buy_Symbiotec_Pharmalab_shares_after_this_news\"><\/span><strong>Should I buy Symbiotec Pharmalab shares after this news?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The deal is a positive signal, but the valuation is rich and deal economics are undisclosed. Use a stop-loss and consult a SEBI-registered adviser.<\/p>\n<div class=\"faq-schema\"><script type=\"application\/ld+json\">{\"@context\":\"https:\/\/schema.org\",\"@type\":\"FAQPage\",\"mainEntity\":[{\"@type\":\"Question\",\"name\":\"What is the Symbiotec Pharmalab share price today?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The Symbiotec Pharmalab share price was Rs 1,198 at 10:12 AM on 1 October 2026, up 1.8 percent, after touching a fresh 52-week high of Rs 1,222.50.\"}},{\"@type\":\"Question\",\"name\":\"What deal has Symbiotec's subsidiary signed?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"Knovea Pharmaceutical, a wholly owned subsidiary of Symbiotec Pharmalab, signed a definitive agreement granting a global pharmaceutical company exclusive US rights to commercialise two dual-chamber vial-based injectable products.\"}},{\"@type\":\"Question\",\"name\":\"Who is the partner in the Knovea Pharmaceutical deal?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The partner's name was not disclosed in the announcement reviewed.\"}},{\"@type\":\"Question\",\"name\":\"Were financial terms of the deal disclosed?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"No. The agreement's financial terms, including any upfront payments or royalties, were not disclosed.\"}},{\"@type\":\"Question\",\"name\":\"Is the Symbiotec Pharmalab share price expensive?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The P\/E of 68.77 is nearly double the pharmaceutical industry average of 38.34, reflecting high growth expectations.\"}},{\"@type\":\"Question\",\"name\":\"What are the key technical levels for the Symbiotec Pharmalab share price?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The key levels are SuperTrend support at Rs 980.78 and the 20-day average of Rs 1,097.93. The RSI is 55.3.\"}},{\"@type\":\"Question\",\"name\":\"What is a dual-chamber vial injectable?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"It is a specialised injectable format that keeps two components, such as a drug and a diluent, separate until just before administration.\"}},{\"@type\":\"Question\",\"name\":\"Should I buy Symbiotec Pharmalab shares after this news?\",\"acceptedAnswer\":{\"@type\":\"Answer\",\"text\":\"The deal is a positive signal, but the valuation is rich and deal economics are undisclosed. Use a stop-loss and consult a SEBI-registered adviser.\"}}]}<\/script><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Symbiotec&#8217;s US arm signed an exclusive deal for two injectables, and the stock hit a fresh 52-week high. Here is the deal, the levels and the risks.<\/p>\n","protected":false},"author":38,"featured_media":282791,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[1007,1019],"class_list":["post-282792","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-pharma-stocks","tag-stock-market"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["282791"],"rank_math_title":["Symbiotec Pharmalab Share Price Hits 52-Week High on US Deal"],"rank_math_description":["Symbiotec Pharmalab share price is Rs 1,198, up 1.8%, after a subsidiary signed a US deal for two dual-chamber vial injectables. Levels and risks explained."],"rank_math_focus_keyword":["Symbiotec Pharmalab share price"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/10\/symbiotec-s-us-arm-signs-an-exclusive-deal-for-two-injectables-and-the-stock.webp","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/282792","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=282792"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/282792\/revisions"}],"predecessor-version":[{"id":282793,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/282792\/revisions\/282793"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/282791"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=282792"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=282792"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=282792"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}